直肠癌术前放化疗疗效是否受ACE抑制剂影响:荷兰癌症登记研究
该回顾性队列研究链接荷兰PHARMO数据库、病理登记和癌症登记,纳入2010–2015年接受术前放化疗后手术的345例直肠癌患者,比较使用与不使用ACEIs/ARBs者的病理完全缓解率。结果显示使用ACEIs/ARBs者pCR为17.4%,未使用者为14.6%(p=0.595),多因素分析未证实ACEIs/ARBs对肿瘤反应的增强效应。
要点
- 345例中92例(26.7%)治疗期间使用ACEIs/ARBs,两组pCR率无统计学差异。
- 良好反应(ypT0-1N0)率在ACEIs/ARBs组为21.7%,未使用组为19.4%(p=0.724)。
- 多因素分析显示使用β受体阻滞剂与pCR升高相关(OR 2.3,95%CI 1.0–5.4)。
核心结论
- 在本回顾性队列中,使用ACEIs/ARBs与直肠癌术前放化疗后的肿瘤反应无关,未能证实其潜在增强效应。
研究设计与样本
- 回顾性队列研究,数据来自PHARMO数据库网络、荷兰病理登记和荷兰癌症登记链接,纳入2010–2015年接受术前放化疗后手术的直肠癌患者345例。
主要发现
- 345例患者中92例(26.7%)治疗期间使用ACEIs/ARBs,中位年龄65岁(范围30–85)。
- 使用ACEIs/ARBs者pCR(ypT0N0)为17.4%,未使用者为14.6%(p=0.595)。
- 使用ACEIs/ARBs者良好反应(ypT0-1N0)为21.7%,未使用者为19.4%(p=0.724)。
- 多因素分析(校正背景变量和合并用药)显示使用β受体阻滞剂者pCR升高(OR 2.3,95%CI 1.0–5.4)。
临床怎么用
- 对于接受术前放化疗的直肠癌患者,使用ACEIs/ARBs无需因期望增强肿瘤反应而调整。
- β受体阻滞剂与pCR升高的关联值得进一步研究,但当前证据不足以改变临床实践。
局限性
- 本研究为回顾性队列研究,样本量有限(345例),ACEIs/ARBs使用组仅92例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The aim of this study was to assess the effect of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on tumor response to preoperative chemoradiation for rectal cancer. MATERIALS AND METHODS: Data on patients who received chemoradiation prior to surgery for rectal cancer between 2010 and 2015 were retrieved from linkage between the PHARMO Database Network, Dutch Pathology Registry and Netherlands Cancer Registry. Pathological complete response rates (pCR) were compared between patients who did or did not use ACEIs/ARBs during treatment. Multivariable analysis was performed using logistic regression. RESULTS: Out of 345 patients, 92 patients (26.7%) used ACEIs/ARBs during treatment. Median age was 65 years (range 30-85). Older and male patients were more likely to use ACEIs/ARBs. pCR (ypT0N0) was observed in 17.4% of patients using ACEIs/ARBs compared to 14.6% of patients who did not use ACEIs/ARBs (p = 0.595). A good response (ypT0-1N0) was observed in 21.7% of ACEIs/ARBs patients vs. 19.4% of patients who did not use ACEIs/ARBs (p = 0.724). Multivariable analysis, taking into account background variables and co-medication, showed increased pCR in patients using beta-blockers (odds ratio 2.3, 95% confidence interval 1.0-5.4). CONCLUSION: In this retrospective cohort, the use of ACEIs/ARBs was not associated with tumor response to preoperative chemoradiation in rectal cancer patients. Thereby, the suggested potentiating effect of ACEIS/ARBs could not be confirmed in our study. Further research could be directed to investigate a possible benefit of beta-blockers or other anti-hypertensive drugs.
引用
- Rombouts AJ, Hugen N, Verhoeven RH, et al. Is preoperative chemoradiation in rectal cancer patients modulated by ACE inhibitors? Results from the Dutch Cancer Registry. Radiother Oncol. 2019. PMID: 31252299. doi:10.1016/j.radonc.2019.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。